Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Europe and Middle East & Africa Meningitis Diagnostic Testing Market

4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights
5.1. Key Success Factors for Top Players
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid /long term impact)
5.3. Key Industry Developments (product launch, product approvals, business expansion, etc.)
5.4. Regulatory Scenario

6. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, By Product, 2017–2031
6.3.1. Latex Agglutination Tests
6.3.2. Lateral Flow Assay
6.3.3. PCR Assay
6.3.4. ELISA Tests
6.3.5. Culture Test
6.3.6. Others
6.4. Market Attractiveness Analysis, By Product

7. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type, 2017–2031
7.3.1. Syndromic Full Multiplex Panel
7.3.2. Low Plex Panel
7.4. Market Attractiveness Analysis, By Type

8. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, By End-user, 2017–2031
8.4. Market Attractiveness Analysis, By End-user

9. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Region
9.1. Key Findings
9.2. Market Value Forecast, By Region

10. Europe Meningitis Diagnostic Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, By Product, 2017–2031
10.2.1. Latex Agglutination Tests
10.2.2. Lateral Flow Assay
10.2.3. PCR Assay
10.2.4. ELISA Tests
10.2.5. Culture Test
10.2.6. Others
10.3. Market Value Forecast, By Type, 2017–2031
10.3.1. Syndromic Full Multiplex Panel
10.3.2. Low Plex Panel
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Diagnostic Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. Germany
10.5.1.1. Market Value Forecast, by Product, 2017–2031
10.5.1.1.1. Latex Agglutination Tests
10.5.1.1.2. Lateral Flow Assay
10.5.1.1.3. PCR Assay
10.5.1.1.4. ELISA Tests
10.5.1.1.5. Culture Test
10.5.1.1.6. Others
10.5.1.2. Market Value Forecast, by Type, 2017–2031
10.5.1.2.1. Syndromic Full Multiplex Panel
10.5.1.2.2. Low Plex Panel
10.5.1.3. Market Value Forecast, by End-user, 2017–2031
10.5.1.3.1. Hospitals
10.5.1.3.2. Diagnostic Centers
10.5.1.3.3. Others
10.5.2. U.K.
10.5.2.1. Market Value Forecast, by Product, 2017–2031
10.5.2.1.1. Latex Agglutination Tests
10.5.2.1.2. Lateral Flow Assay
10.5.2.1.3. PCR Assay
10.5.2.1.4. ELISA Tests
10.5.2.1.5. Culture Test
10.5.2.1.6. Others
10.5.2.2. Market Value Forecast, by Type, 2017–2031
10.5.2.2.1. Syndromic Full Multiplex Panel
10.5.2.2.2. Low Plex Panel
10.5.2.3. Market Value Forecast, by End-user, 2017–2031
10.5.2.3.1. Hospitals
10.5.2.3.2. Diagnostic Centers
10.5.2.3.3. Others
10.5.3. France
10.5.3.1. Market Value Forecast, by Product, 2017–2031
10.5.3.1.1. Latex Agglutination Tests
10.5.3.1.2. Lateral Flow Assay
10.5.3.1.3. PCR Assay
10.5.3.1.4. ELISA Tests
10.5.3.1.5. Culture Test
10.5.3.1.6. Others
10.5.3.2. Market Value Forecast, by Type, 2017–2031
10.5.3.2.1. Syndromic Full Multiplex Panel
10.5.3.2.2. Low Plex Panel
10.5.3.3. Market Value Forecast, by End-user, 2017–2031
10.5.3.3.1. Hospitals
10.5.3.3.2. Diagnostic Centers
10.5.3.3.3. Others
10.5.4. Italy
10.5.4.1. Market Value Forecast, by Product, 2017–2031
10.5.4.1.1. Latex Agglutination Tests
10.5.4.1.2. Lateral Flow Assay
10.5.4.1.3. PCR Assay
10.5.4.1.4. ELISA Tests
10.5.4.1.5. Culture Test
10.5.4.1.6. Others
10.5.4.2. Market Value Forecast, by Type, 2017–2031
10.5.4.2.1. Syndromic Full Multiplex Panel
10.5.4.2.2. Low Plex Panel
10.5.4.3. Market Value Forecast, by End-user, 2017–2031
10.5.4.3.1. Hospitals
10.5.4.3.2. Diagnostic Centers
10.5.4.3.3. Others
10.5.5. Spain
10.5.5.1. Market Value Forecast, by Product, 2017–2031
10.5.5.1.1. Latex Agglutination Tests
10.5.5.1.2. Lateral Flow Assay
10.5.5.1.3. PCR Assay
10.5.5.1.4. ELISA Tests
10.5.5.1.5. Culture Test
10.5.5.1.6. Others
10.5.5.2. Market Value Forecast, by Type, 2017–2031
10.5.5.2.1. Syndromic Full Multiplex Panel
10.5.5.2.2. Low Plex Panel
10.5.5.3. Market Value Forecast, by End-user, 2017–2031
10.5.5.3.1. Hospitals
10.5.5.3.2. Diagnostic Centers
10.5.5.3.3. Others
10.5.6. Benelux
10.5.6.1. Market Value Forecast, by Product, 2017–2031
10.5.6.1.1. Latex Agglutination Tests
10.5.6.1.2. Lateral Flow Assay
10.5.6.1.3. PCR Assay
10.5.6.1.4. ELISA Tests
10.5.6.1.5. Culture Test
10.5.6.1.6. Others
10.5.6.2. Market Value Forecast, by Type, 2017–2031
10.5.6.2.1. Syndromic Full Multiplex Panel
10.5.6.2.2. Low Plex Panel
10.5.6.3. Market Value Forecast, by End-user, 2017–2031
10.5.6.3.1. Hospitals
10.5.6.3.2. Diagnostic Centers
10.5.6.3.3. Others
10.5.7. Poland
10.5.7.1. Market Value Forecast, by Product, 2017–2031
10.5.7.1.1. Latex Agglutination Tests
10.5.7.1.2. Lateral Flow Assay
10.5.7.1.3. PCR Assay
10.5.7.1.4. ELISA Tests
10.5.7.1.5. Culture Test
10.5.7.1.6. Others
10.5.7.2. Market Value Forecast, by Type, 2017–2031
10.5.7.2.1. Syndromic Full Multiplex Panel
10.5.7.2.2. Low Plex Panel
10.5.7.3. Market Value Forecast, by End-user, 2017–2031
10.5.7.3.1. Hospitals
10.5.7.3.2. Diagnostic Centers
10.5.7.3.3. Others
10.5.8. Norway
10.5.8.1. Market Value Forecast, by Product, 2017–2031
10.5.8.1.1. Latex Agglutination Tests
10.5.8.1.2. Lateral Flow Assay
10.5.8.1.3. PCR Assay
10.5.8.1.4. ELISA Tests
10.5.8.1.5. Culture Test
10.5.8.1.6. Others
10.5.8.2. Market Value Forecast, by Type, 2017–2031
10.5.8.2.1. Syndromic Full Multiplex Panel
10.5.8.2.2. Low Plex Panel
10.5.8.3. Market Value Forecast, by End-user, 2017–2031
10.5.8.3.1. Hospitals
10.5.8.3.2. Diagnostic Centers
10.5.8.3.3. Others
10.5.9. Sweden
10.5.9.1. Market Value Forecast, by Product, 2017–2031
10.5.9.1.1. Latex Agglutination Tests
10.5.9.1.2. Lateral Flow Assay
10.5.9.1.3. PCR Assay
10.5.9.1.4. ELISA Tests
10.5.9.1.5. Culture Test
10.5.9.1.6. Others
10.5.9.2. Market Value Forecast, by Type, 2017–2031
10.5.9.2.1. Syndromic Full Multiplex Panel
10.5.9.2.2. Low Plex Panel
10.5.9.3. Market Value Forecast, by End-user, 2017-2031
10.5.9.3.1. Hospitals
10.5.9.3.2. Diagnostic Centers
10.5.9.3.3. Others
10.5.10. Denmark
10.5.10.1. Market Value Forecast, by Product, 2017–2031
10.5.10.1.1. Latex Agglutination Tests
10.5.10.1.2. Lateral Flow Assay
10.5.10.1.3. PCR Assay
10.5.10.1.4. ELISA Tests
10.5.10.1.5. Culture Test
10.5.10.1.6. Others
10.5.10.2. Market Value Forecast, by Type, 2017–2031
10.5.10.2.1. Syndromic Full Multiplex Panel
10.5.10.2.2. Low Plex Panel
10.5.10.3. Market Value Forecast, by End-user, 2017–2031
10.5.10.3.1. Hospitals
10.5.10.3.2. Diagnostic Centers
10.5.10.3.3. Others
10.5.11. Finland
10.5.11.1. Market Value Forecast, by Product, 2017–2031
10.5.11.1.1. Latex Agglutination Tests
10.5.11.1.2. Lateral Flow Assay
10.5.11.1.3. PCR Assay
10.5.11.1.4. ELISA Tests
10.5.11.1.5. Culture Test
10.5.11.1.6. Others
10.5.11.2. Market Value Forecast, by Type, 2017–2031
10.5.11.2.1. Syndromic Full Multiplex Panel
10.5.11.2.2. Low Plex Panel
10.5.11.3. Market Value Forecast, by End-user, 2017–2031
10.5.11.3.1. Hospitals
10.5.11.3.2. Diagnostic Centers
10.5.11.3.3. Others
10.5.12. Austria
10.5.12.1. Market Value Forecast, by Product, 2017–2031
10.5.12.1.1. Latex Agglutination Tests
10.5.12.1.2. Lateral Flow Assay
10.5.12.1.3. PCR Assay
10.5.12.1.4. ELISA Tests
10.5.12.1.5. Culture Test
10.5.12.1.6. Others
10.5.12.2. Market Value Forecast, by Type, 2017–2031
10.5.12.2.1. Syndromic Full Multiplex Panel
10.5.12.2.2. Low Plex Panel
10.5.12.3. Market Value Forecast, by End-user, 2017–2031
10.5.12.3.1. Hospitals
10.5.12.3.2. Diagnostic Centers
10.5.12.3.3. Others
10.5.13. Switzerland
10.5.13.1. Market Value Forecast, by Product, 2017–2031
10.5.13.1.1. Latex Agglutination Tests
10.5.13.1.2. Lateral Flow Assay
10.5.13.1.3. PCR Assay
10.5.13.1.4. ELISA Tests
10.5.13.1.5. Culture Test
10.5.13.1.6. Others
10.5.13.2. Market Value Forecast, by Type, 2017–2031
10.5.13.2.1. Syndromic Full Multiplex Panel
10.5.13.2.2. Low Plex Panel
10.5.13.3. Market Value Forecast, by End-user, 2017–2031
10.5.13.3.1. Hospitals
10.5.13.3.2. Diagnostic Centers
10.5.13.3.3. Others
10.5.14. Rest of Europe
10.5.14.1. Market Value Forecast, by Product, 2017–2031
10.5.14.1.1. Latex Agglutination Tests
10.5.14.1.2. Lateral Flow Assay
10.5.14.1.3. PCR Assay
10.5.14.1.4. ELISA Tests
10.5.14.1.5. Culture Test
10.5.14.1.6. Others
10.5.14.2. Market Value Forecast, by Type, 2017–2031
10.5.14.2.1. Syndromic Full Multiplex Panel
10.5.14.2.2. Low Plex Panel
10.5.14.3. Market Value Forecast, by End-user, 2017–2031
10.5.14.3.1. Hospitals
10.5.14.3.2. Diagnostic Centers
10.5.14.3.3. Others
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Type
10.6.3. By End-user
10.6.4. By Country

11. Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Latex Agglutination Tests
11.2.2. Lateral Flow Assay
11.2.3. PCR Assay
11.2.4. ELISA Tests
11.2.5. Culture Test
11.2.6. Others
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Syndromic Full Multiplex Panel
11.3.2. Low Plex Panel
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Diagnostic Centers
11.4.3. Others
11.5. Market Value Forecast, by Country, 2017–2031
11.5.1. GCC Countries
11.5.1.1. Market Value Forecast, by Product, 2017–2031
11.5.1.1.1. Latex Agglutination Tests
11.5.1.1.2. Lateral Flow Assay
11.5.1.1.3. PCR Assay
11.5.1.1.4. ELISA Tests
11.5.1.1.5. Culture Test
11.5.1.1.6. Others
11.5.1.2. Market Value Forecast, by Type, 2017–2031
11.5.1.2.1. Syndromic Full Multiplex Panel
11.5.1.2.2. Low Plex Panel
11.5.1.3. Market Value Forecast, by End-user, 2017–2031
11.5.1.3.1. Hospitals
11.5.1.3.2. Diagnostic Centers
11.5.1.3.3. Others
11.5.2. South Africa
11.5.2.1. Market Value Forecast, by Product, 2017–2031
11.5.2.1.1. Latex Agglutination Tests
11.5.2.1.2. Lateral Flow Assay
11.5.2.1.3. PCR Assay
11.5.2.1.4. ELISA Tests
11.5.2.1.5. Culture Test
11.5.2.1.6. Others
11.5.2.2. Market Value Forecast, by Type, 2017–2031
11.5.2.2.1. Syndromic Full Multiplex Panel
11.5.2.2.2. Low Plex Panel
11.5.2.3. Market Value Forecast, by End-user, 2017–2031
11.5.2.3.1. Hospitals
11.5.2.3.2. Diagnostic Centers
11.5.2.3.3. Others
11.5.3. Rest of Middle East & Africa
11.5.3.1. Market Value Forecast, by Product, 2017–2031
11.5.3.1.1. Latex Agglutination Tests
11.5.3.1.2. Lateral Flow Assay
11.5.3.1.3. PCR Assay
11.5.3.1.4. ELISA Tests
11.5.3.1.5. Culture Test
11.5.3.1.6. Others
11.5.3.2. Market Value Forecast, by Type, 2017–2031
11.5.3.2.1. Syndromic Full Multiplex Panel
11.5.3.2.2. Low Plex Panel
11.5.3.3. Market Value Forecast, by End-user, 2017–2031
11.5.3.3.1. Hospitals
11.5.3.3.2. Diagnostic Centers
11.5.3.3.3. Others
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Type
11.6.3. By End-user
11.6.4. By Country
12. Competition Landscape
12.1. Company Profiles
12.1.1. Thermo Fisher Scientific, Inc.
12.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.1.2. Product Portfolio
12.1.1.3. SWOT Analysis
12.1.1.4. Strategic Overview
12.1.2. BioFire Diagnostics
12.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.2.2. Product Portfolio
12.1.2.3. SWOT Analysis
12.1.2.4. Strategic Overview
12.1.3. Fast Track Diagnostics Ltd. (FTD) – Siemens Healthineers
12.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.3.2. Product Portfolio
12.1.3.3. SWOT Analysis
12.1.3.4. Strategic Overview
12.1.4. Bio-Rad Laboratories, Inc.
12.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.4.2. Product Portfolio
12.1.4.3. SWOT Analysis
12.1.4.4. Strategic Overview
12.1.5. IMMY
12.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.5.2. Product Portfolio
12.1.5.3. SWOT Analysis
12.1.5.4. Strategic Overview
12.1.6. Nanosphere (Luminex Corporation)
12.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.6.2. Product Portfolio
12.1.6.3. SWOT Analysis
12.1.6.4. Strategic Overview
12.1.7. Seegene, Inc.
12.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.7.2. Product Portfolio
12.1.7.3. SWOT Analysis
12.1.7.4. Strategic Overview
12.1.8. Qnostics
12.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.8.2. Product Portfolio
12.1.8.3. SWOT Analysis
12.1.8.4. Strategic Overview
12.1.9. ELITechGroup
12.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.9.2. Product Portfolio
12.1.9.3. SWOT Analysis
12.1.9.4. Strategic Overview
12.1.10. Abbott Laboratories
12.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.10.2. Product Portfolio
12.1.10.3. SWOT Analysis
12.1.10.4. Strategic Overview
12.1.11. Other Prominent Players



List of Figures


Figure 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Product Type (2020)

Figure 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by End-user (2020)

Figure 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Panel Type (2020)

Figure 05: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Region (2020)

Figure 06: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 07: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Latex Agglutination Tests, 2017–2031

Figure 08: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Lateral Flow Assay, 2017–2031

Figure 09: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by PCR Assay, 2017–2031

Figure 10: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by ELISA Tests, 2017–2031

Figure 11: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Culture Test, 2017–2031

Figure 12: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by others, 2017–2031

Figure 13: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 14: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 15: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Syndromic Full Multiplex Panel, 2017–2031

Figure 16: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Low Plex Panel, 2017–2031

Figure 17: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 18: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 19: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Hospitals, 2017–2031

Figure 20: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031

Figure 21: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Others, 2017–2031

Figure 22: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 23: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Region, 2020 and 2031

Figure 24: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Region, 2021-2031

Figure 25: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 26: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 27: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 28: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 29: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-User, 2020 and 2031

Figure 30: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-User, 2021–2031

Figure 31: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Country, 2020 and 2031

Figure 32: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country, 2021–2031

Figure 33: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 34: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 35: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 36: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 37: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 38: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 39: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 40: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 41: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 42: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 43: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 44: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 45: France Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 46: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 47: France Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 48: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 49: France Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 50: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 51: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 52: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 53: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 54: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 55: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 56: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 57: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 58: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 59: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 60: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 61: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 62: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 63: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 64: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 65: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 66: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 67: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 68: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 69: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 70: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 71: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 72: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 73: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 74: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 75: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 76: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 77: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 78: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 79: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 80: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 81: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 82: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 83: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 84: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 85: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 86: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 87: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 88: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 89: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 90: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 91: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 92: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 93: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 94: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 95: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 96: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 97: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 98: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 99: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 100: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 101: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 102: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 103: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 104: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 105: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 106: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 107: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 108: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 109: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 110: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 111: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 112: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 113: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 114: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 115: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 116: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 117: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 118: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 119: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 120: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 121: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 122: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 123: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 124: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 125: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 126: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 127: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 128: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 129: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 130: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 131: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 132: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 133: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 134: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 135: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 136: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 137: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 138: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 139: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 140: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 141: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 142: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

List of Tables


Table 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

Table 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 06: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 07: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-User, 2017–2031

Table 08: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 10: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 11: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 13: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 14: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 15: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 16: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 17: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 18: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 19: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 20: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 22: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 23: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 24: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 25: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 26: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 27: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 28: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 29: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 30: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 31: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 32: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 33: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 34: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 35: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 36: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 37: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 38: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 39: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 40: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 41: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 42: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 43: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 44: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 45: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 46: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 47: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 48: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 49: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 50: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 51: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 52: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 53: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 54: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 55: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 56: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 57: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 58: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 59: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 60: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 61: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 62: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 63: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031